| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.0016 | 1 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | 0.0067 | 1 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |